Vivek Subbiah: An enlightening panel discussion on the latest advancements in oncology at SCRI meeting
Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on LinkedIn:
“Absolutely thrilled to have been part of an enlightening panel discussion with esteemed colleagues Drs. Navneet Majhail, Melissa Johnson, Dax Kurbegov, Richard Geer and Andy Kennedy on the latest advancements in oncology at Sarah Cannon Research Institute meeting.
Here are some key takeaways:
- Targeted Therapy Innovations eg. KRAS inhibitors
- CAR-T Cell Therapy
- CAR-NK therapies
- Novel Immune Checkpoint Inhibitors
- Tumor Agnostic Therapies
- Antibody-Drug Conjugates (ADCs), Bi-specifics and Radioligands
- Next-Generation Sequencing (NGS) and Liquid Biopsies
- AI in Oncology
- Robotic surgeries/Outpatient surgeries
- and much much more
Excited for what’s ahead!”
More posts featuring Vivek Subbiah.
Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research and former Associate Professor in the Department of Investigational Cancer Therapeutics at the MD Anderson Cancer.
He focuses on translational cancer research and the design and implementation of early-phase biomarker-driven clinical trials. His work specifically targets antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials. He has also received the Yvonne Award 2024 by OncoDaily in the “Voice of Oncology” category.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023